Our Research
MDMA for Depression in People Living with HIV
The neurobiological effects of MDMA reduce defenses and fear of emotional injury, enhance communication and introspection, and increase sympathy and compassion. These effects in a therapeutic setting allow the patient to enter a psychological state that enhances the efficacy of therapy and intensifies the healing that can be achieved. For these reasons, we believe that MDMA may be effective in treating the depression that is associated with a positive HIV diagnosis.
This study protocol has been approved by the Multidisciplinary Association for Psychedelic Studies (MAPS), and is now under review by the FDA. This clinical trial is not yet open for recruitment and screening.
For more information about this study, reach out to our clinical trial coordinator at annapayton@berkeley.edu
Ketamine for Eating Disorders
There are several case reports which suggest that ketamine may play a role in treating eating disorders. We are in the process of writing a clinical trial proposal to further evaluate the safety and efficacy of KAP for treatment of eating disorders.
This clinical trial is not yet open for recruitment and screening.
Ketamine for Tobacco Cessation
There is some evidence that ketamine could be a useful tool for curbing tobacco addiction. We are developing protocols to evaluate the role of ketamine in smoking cessation.
This clinical trial is not yet open for recruitment and screening.
Interested in learning more?
Stay up to date with our research by subscribing to our email list below.
Make a Donation
Help us fund our research endeavors. Contribute to the future of psychedelic science.